Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Up 71.6% in February

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 182,800 shares, a growth of 71.6% from the February 13th total of 106,500 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Cyclacel Pharmaceuticals in a research note on Saturday. They set a “sell” rating for the company.

Insiders Place Their Bets

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 23.97% of the stock is owned by corporate insiders.

Cyclacel Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ CYCC opened at $0.30 on Friday. Cyclacel Pharmaceuticals has a 52-week low of $0.29 and a 52-week high of $4.00. The firm has a fifty day moving average of $0.35 and a 200-day moving average of $0.58. The stock has a market capitalization of $1.87 million, a PE ratio of -0.03 and a beta of 0.28.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.